White House appoints NCI Director Andrew von Eschenbach acting FDA commissioner after Lester Crawford resigns.
Von Eschenbach says he will continue as NCI director and give both jobs “100 percent.”
Members of Congress say that won’t work.
Legal experts say too many conflicts involved. HHS gave von Eschenbach a waiver for his role in C-Change.
After a “humble” start at NCI, von Eschenbach set unachievable goal.
Trending Stories
- With five-year cancer survival at an all-time high, does this mean people are living longer?
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- An oncologist navigates terminal sarcoma, insurmountable debt, and “a legacy of grief”
How colleagues and Fargo, ND, neighbors came together to help the Erickson-Abou Zahrs - Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched - House passes three-year extension of ACA subsidies with bipartisan support
- When “safe and effective” is not “reasonable and necessary”
We can curb excessive drug dosing and improve the quality of cancer care









